Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

About one million Americans carry the hepatitis B virus (HBV) which can lead to liver cancer. But the search for treatments has been stymied by the lack of a suitable animal for testing new drugs. Rodents don’t get HBV, and chimpanzees, which do, are expensive.

XTL Biopharmacueticals in Rehovot, Israel, has come up with a solution by creating a mouse with a bit of human liver inside it. XTL’s recipe: destroy the immune system of a normal mouse with gamma rays. Next, transplant a peppercorn-sized fragment of HBV-infected human liver, along with bone marrow from an immune-deficient mouse. XTL calls the resulting creature a “trimera” because it has components of three different animals. Since the mouse’s weak immune system doesn’t reject the human cells, there is time to test the effects of anti-viral drugs. XTL hopes to develop trimera models for cancer.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me